临床试验登记· Hansoh BioMedical R&D Company · ClinicalTrials.gov·· 23 hours agoScore28
An Open-label Study of HS-20137 in Participants With Moderate-to-Severe Plaque Psoriasis
In brief
Hansoh BioMedical R&D Company has registered NCT07879885, a Phase 2 open-label study evaluating the safety and efficacy of HS-20137 in moderate-to-severe plaque psoriasis. The study plans to enroll 390 participants, is currently recruiting, and the intervention is a biological agent, HS-20137.
Source: 临床试验登记 · clinicaltrials.gov